Due to the site upgrade, your MY ACCOUNT logins will need to be updated. Please access Forgot Your Password to make this change. If you do not have an account, click here.

Vinpocetine improves blood flow and energy use in the brains of stroke patients

Mar 17, 2005

In a study of patients who suffered an ischemic stroke 7 patients were given a daily intravenous infusion without Vinpocetine and six were given the same infusion but with the addition of Vinpocetine for 14 days in a double-blind study. A pet scan was used along with transcranial doppler parameters to measure the effectiveness of the treatments. Blood flow throughout the brain improved with the addition of Vinpocetine, while the ability to use glucose, the chief substrate for energy production improved in particular, but important regions of the brain. The ability to use glucose for energy production improved significantly in the thalamus and the caudate neuleus, and cerebral blood flow improved throughout the brain but more significantly so in these areas with a 36% improvement in the flow of blood in the thalamus and a 37% improvement in the caudate neucleus. The study shows that a two week course of treatment with intravenous Vinpocetine improves blood flow throughout the brain after an ischemic stroke and especially improves it in the thalamus and the caudate neucleus. The distrubution of glucose for energy use also improves but in this study, in particular brain regions. The study is published in the March 2005 issue of the Journal of Neurological Sciences.

Commentary by Jerry Hickey, R.Ph.

The caudate nucleus helps control voluntary movements involving large limbs (e.g. adjusting the arm so the fingers can pick something up), it also regulates and organizes information being sent to the brain. The thalamus regulates sensory input and motor control. It is important for sight, hearing, taste, smell, touch, temperature recognition, balance, pain, pleasure, arousal, control of movement, muscle control and sensing the bodies relationship to its physical environment. This was a short study and a longer study probably would demonstrate even greater benefit. I take 10mg of Vinpocetine almost every morning and notice improved brain energy and efficiency on the days I take it.

Both Green and Black Tea Polyphenols inhibit lung cancer in lab animals

Tea polyphenols have been shown by different researchers to inhibit lung cancer in different animal models. This includes lung cancer caused by different cancer causing chemicals including some of those more troublesome ones found in pollution and in tobacco smoke. The te ingredients reduced the number and size of tumors and even in the number of animals that developed lung cancer. The Green Tea polyphenol EGCG, and the Black Tea polyphenol Theaflavins have both been shown to be effective. The Black Tea preparations have reduced thhe number of animals with cancer and the number of lung tumors in mice, and also inhibited the transformation of lung adenomas to adenocarcinoma. In Green Tea it is the EGCG that is effective. In many experiments, the consumption of tea preperations resulted in the reduction of body fat and body weight, and this factor may also contribute to the decreased risk of lung canmcer. The review was performed at the Susan Lehman Cullman Laboratory for Cancer research , Ernest Mario School of Pharmacy, Rutgers University, and is published in the January-February 2005 issue of the journal Experimental Lung Research.

New and powerful way that Green Tea's EGCG inhibits cancer discovered

Scientists at both the University of Murcia in Spain, and the John Innes Center in England have found a powerful way that the most important Green Tea Polyphenol, EGCG fights an existing cancer. EGCG inhibits the enzyme dihydrofolate reductase (DHFR). DHRF is a recognized and established target for cancer chemotherapeutic drugs, and this may be the first study showing that Green tea's EGCG targets the same cancer site as established drugs, except without the toxicity and this is in addition to the other targets EGCG has for reducing the risk of developing and also fighting a cross section of cancers. Targetting DHFR is the same way that the commonly used chemotherapeutic drug methotrexate works. The study is publsihed in the current issue of the journal Cancer Research.